Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
The unique ORS effervescent tablet has been developed according to the latest guidelines of the WHO. It has a substantial marketshare in several countries. We are looking for partners to further expand this success. More
Cellophil™ is a platform of novel polymers based on amino-acid groups. The platform polymers show superior biocompatibility and can be loaded with drugs for controlled release. More
Cripto-1 expression increases the expression of TNF-alpha in CD4+ T cells in tissues affected by chronic inflammatory disease. More
Our clients have a patent available for acquisition or licensing for a novel preparation method of Rabeprazole in the EU and Turkey (excluding Portugal) More
Multilayered controlled release oral solid pharmaceutical composition in tablet form suitable for oral administration comprising at least two layers containing active material in association with excipients and additives. More
This TACE inhibitory protein could be used as a new therapeutic agent against chronic inflammatory diseases that are mediated by TNF-alpha. More
Recently characterized MUC17 gene highly specific for pancreatic cancer. More
Design, synthesis and biological evaluation of novel NO-releasing NSAIDs possessing a N-diazen-1-ium-1,2-diolate (NONOate), which offers additional advantages compared with organic nitrate-based NO-NSAIDs More
Cardiovascular physiology and atherosclerosis - prevention of cardiovascular complications in patients with renal failure or increased carbamylation. More
Related Reports
Market Research Reports provided by reports.innovaro.com
Jan 2008 - 148 pages - $1,740
Dec 2010 - 30 pages - $500
Dec 2010 - 41 pages - $500
Mar 2011 - 41 pages - $500
Dec 2010 - 40 pages - $500
Mar 2011 - 40 pages - $500
Nov 2010 - 933 pages - $1,495
Nov 2010 - 324 pages - $1,495
Nov 2011 - 7 pages - $3,835
Jun 2006 - 278 pages - $2,495
Your selection
- Therapeutic target
- Gastrointestinal del
Browse By
- Industry sector
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Pharmaceutical
- Research tools
- Therapeutic target
- Appendicitis
- Cholangitis, sclerosing
- Colitis
- Colitis, ulcerative
- Constipation
- Crohn's disease
- Diarrhea
- Dyspepsia
- Electrolyte replacement
- Emesis
- Emesis, motion
- Esophagitis
- Flatulence
- Food poisoning
- Gastritis
- Gastroesophageal reflux disorder
- Gastrointestinal (other)
- Gastrointestinal secretions
- Gastroprokinetic
- Helicobacter pylori
- Inflammatory bowel disease
- Irritable bowel syndrome
- Nausea
- Pancreatitis
- Ulcer
- Ulcer, gastric
- Ulcer, gastroduodenal
- Ulcer, peptic
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2012 Innovaro Europe Ltd 
All rights reserved. Terms and Conditions | Contact us